Related Experiment Videos
[Chronic inflammatory demyelinating polyneuropathy]
H Köller1, B C Kieseier, S Jander
1Neurologische Klinik, Universitätsklinikum Düsseldorf, Düsseldorf. koellerh@uni-duesseldorf.de
Der Nervenarzt
|April 23, 2003
Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated peripheral nerve disorder. Research suggests immune mechanisms are involved, but specific targets remain unknown, impacting diagnosis and treatment strategies.
Area of Science:
- Neurology
- Immunology
- Peripheral Nervous System Disorders
Context:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disorder affecting the peripheral nervous system.
- Prevalence is estimated at 1-2 per 100,000 individuals.
- While immune pathomechanisms are implicated, specific target antigens are yet to be identified.
Purpose:
- To review the current understanding of Chronic inflammatory demyelinating polyneuropathy (CIDP).
- To discuss diagnostic criteria and emerging imaging techniques.
- To highlight the therapeutic potential of immunomodulatory treatments.
Summary:
- CIDP presents with varying clinical manifestations, including classic symmetrical deficits and distinct pure motor or sensory subtypes.
- Diagnostic confirmation relies on electrophysiological evidence of demyelination, biopsy findings, and elevated cerebrospinal fluid (CSF) protein.
- Magnetic resonance imaging (MRI) of nerve roots and plexuses aids in differential diagnosis.
Impact:
- Advances in understanding CIDP pathogenesis are crucial for developing targeted therapies.
- Improved diagnostic tools enhance early and accurate identification of CIDP.
- Demonstrated efficacy of immunosuppressant and immunomodulatory therapies offers treatment options for patients.